within Pharmacolibrary.Drugs.C_CardiovascularSystem.C08C_SelectiveCalciumChannelBlockersWithMainlyVascularEffects.C08CA16_Clevidipine;

model Clevidipine
  extends Pharmacolibrary.Drugs.ATC.C.C08CA16;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C08CA16</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Clevidipine is an ultrashort-acting dihydropyridine calcium channel blocker used for the rapid reduction of blood pressure in cases of acute hypertension. It is administered intravenously and is approved for use in clinical settings such as perioperative hypertension and hypertensive emergencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following intravenous infusion.</p><h4>References</h4><ol><li><p>Ericsson, H, et al., &amp; Regårdh, CG (1999). Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. <i>European journal of clinical pharmacology</i> 55(1) 61–67. DOI:<a href=&quot;https://doi.org/10.1007/s002280050594&quot;>10.1007/s002280050594</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10206087/&quot;>https://pubmed.ncbi.nlm.nih.gov/10206087</a></p></li><li><p>Zhou, Y, et al., &amp; Li, WY (2014). Pharmacokinetics and tissue distribution of clevidipine and its metabolite in dogs and rats. <i>Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban</i> 34(6) 856–860. DOI:<a href=&quot;https://doi.org/10.1007/s11596-014-1364-3&quot;>10.1007/s11596-014-1364-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25480581/&quot;>https://pubmed.ncbi.nlm.nih.gov/25480581</a></p></li><li><p>Ndefo, UA, et al., &amp; Green, W (2010). Clevidipine: a new intravenous option for the management of acute hypertension. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 67(5) 351–360. DOI:<a href=&quot;https://doi.org/10.2146/ajhp080692&quot;>10.2146/ajhp080692</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20172984/&quot;>https://pubmed.ncbi.nlm.nih.gov/20172984</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Clevidipine;
